

Fukuoka M, Wu YL, Thongprasert S, Sunpa weravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenzov Y, Speake G, Jiang H, Armour A, To KF, Yang JC, Mok TS	Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)	Journal of Clinical Oncology	29(21)	2866-2874	2011
Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Sakahira H, Asami K, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Miyazaki M, Tamura K, Kurata T, Fukuoka M, Nakagawa K	Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.	Journal of Clinical Oncology	28(36)	5240-5246	2011
Tanizaki J, Okamoto I, Okamoto K, Takezawa K, Kuwata K, Yamaguchi H, Nakagawa K	MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations	Journal of Thoracic Oncology	6(10)	1624-1631	2011
Maeda R, Tabata C, Tabata R, Eguchi R, Fujimori Y, Nakano T	Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?	Antioxid Redox Signal.	15	685-689	2011

Hirayama N, Tabata C, Tabata R, Maeda R, Yasumitsu A, Yamada S, Kuribayashi K, Fukuoka K, Nakano T	Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.	Respir Med.	1051	137-142	2011
Weder W, Stahel RA, Baas P, Dafni U, de Perrot M, McCaughan BC, Nakano T, Pass HI, Robinson BWS, Rusch VW, Sugarbaker DJ, Zandwijk N	The MARS feasibility trial: conclusions not supported by data.	Lancet Oncol	12	1093-1094	2011
Sato A, Torii I, Tao L, Song M, Kondo N, Yoshikawa Y, Hashimoto-Tamaoki T, Hasegawa S, Nakano T, Tsujimura T	Establishment of a cell line from a Japanese patient useful for generating and in vivo model of malignant pleural mesothelioma	Cancer Sci	102	648-655	2011
Yoshikawa Y, Sato A, Tsujimura T, Morinaga T, Fukuoka K, Yamada S, Murakami A, Kondo N, Matsumoto S, Okumura Y, Tanaka F, Hasegawa S, Hashimoto-Tamaoki T, Nakano T	Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells	Int J Oncol.	39	1365-1374	2011
N. Kumagai-Takei, M. Maeda, Y. Chen, H. Matsuzaki, S. Lee, Y. Nishimura, J. Hiratsuka and T. Otsuki	Asbestos Induces Reduction of Tumor Immunity	Clinical and Developmental Immunology.		P9	2011
Nishimura Y, Kumagai N, Maeda M, Hayashi H, Fukuoka K, Nakano T, Miura Y, Hiratsuka J, Otsuki T	Suppressive effect of asbestos on cytotoxicity of human NK cells	Int J Immunopath Pharmacol :	Jan-Mar; 24(1Suppl)	5S-10S	2011

Maeda M, Nishimura Y, Hayaishi H, Kumagai N, Chen Y, Murakami S, Miura Y, Hiratsuka J, Kishimoto T, Otsuki T	Reduction of CXCR3 on an in vitro model of continuous asbestos exposure on a human T-cell line, MT-2	Am J Resp Cell Mol Biol	45	470-479	2011
Maeda M, Nishimura Y, Hayaishi H, Kumagai N, Chen Y, Murakami S, Miura Y, Hiratsuka J, Kishimoto T, Otsuki T	Decreased CXCR3 expression in CD4+ T cells exposed to asbestos or derived from asbestos-exposed patients.	Am J Resp Cell Mol Biol	45	795-803	2011
S. Kusaka, Y. Httori, K. Uehara, T. Asano, S. Tanimori, M. Kiriha ta	Synthesis of optically active dodecaborate-containing L-amino acids for BNCT	Applied Radiation and Isotopes	69	1768-1770	2011.
T. Tsukamoto, H. Tanaka, H. Y oshinaga, T. M itsumoto, A. M aruhashi, K. O no and Y. Saku rai	A phantom experiment for the evaluation of whole body exposure during BNCT using cyclotron-based epithermal neutron source (C-BENS)	Appl. Radiat. Isot	69	1830-1833	2011
H. Matsuzaki, M. Maeda, S. Lee, Y. Nishimura, N. Kumagai-Takei, H. hayaishi, S. Yamamoto, T. Hatayama, Y. Kojima, R. Tabata, T. K ishimoto, J. H iratsuka and T. Otsuki	Asbestos-Induced Cellular and Molecular Alteration of Immunocompetent Cells and Their Relationship with Chronic Inflammation and Carcinogenesis	Journal of Biomedicine and Biotechnology			2012
Tada T, Chiba Y, Tsujino K, Fukuda H, Nishimura Y, Kokubo M, Negoro S, Kudoh S, Fukuoka M, Nakagawa K, Nakanishi Y. A	Phase I Study of Chemoradiotherapy with Use of Involved-Field Conformal Radiotherapy and Accelerated Hyperfractionation for Stage III Non-Small-Cell Lung Cancer: WJTOG 3305.	Int J Radiat Oncol Biol Phys	83(1)	327-331	2012

Ichinose Y, Seto T, Sasaki T, Yamanaka T, Okamoto I, Takeda K, Tanaka M, Katakami N, Sawa T, Kudoh S, Saka H, Nishimura Y, Nakagawa K, Fukuoka M	S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706)	J Thorac Oncol.	6(12)	2069-2075	2012
Okada A, Yaguchi T, Kanno T, Gotoh A, Nakano T, Nishizaki T.	PDGF-D/PDGF- β receptor-regulated chemotaxis of malignant mesothelioma cells	Cell Physiol Biochem.	29(1-2)	241-250	2012
Eguchi R, Kubo S, Takeda H, Ohta T, Tabata C, Ogawa H, Nakano T, Fujimori Y	Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells	Carcinogenesis.	33(5)	969-975	2012
Murakami A, Fujimori Y, Yoshikawa Y, Yamada S, Tamura K, Hirayama N, Terada T, Kuribayashi K, Tabata C, Fukuoka K, Tamaoki T, Nakano T	Heme Oxygenase-1 Promoter Polymorphism is Associated with Risk of Malignant Mesothelioma	Lung.	190(3)	333-337	2012

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)

Masahiro Fukuoka, Yi-Long Wu, Sumitra Thongprasert, Patrapim Sunpaweravong, Swan-Swan Leong, Virote Sriuranpong, Tsu-Yi Chao, Kazuhiko Nakagawa, Da-Tong Chu, Nagahiro Saijo, Emma L. Duffield, Yuri Rukazenzov, Georgina Speake, Haiyi Jiang, Alison A. Armour, Ka-Fai To, James Chih-Hsin Yang, and Tony S.K. Mok

See accompanying editorial on page 2843; listen to the podcast by Dr Sequist on www.jco.org/podcast

A B S T R A C T

Purpose

The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma were published previously. This report presents overall survival (OS) and efficacy according to epidermal growth factor receptor (EGFR) biomarker status.

Patients and Methods

In all, 1,217 patients were randomly assigned. Biomarkers analyzed were *EGFR* mutation (amplification mutation refractory system; 437 patients evaluable), *EGFR* gene copy number (fluorescent in situ hybridization; 406 patients evaluable), and EGFR protein expression (immunohistochemistry; 365 patients evaluable). OS analysis was performed at 78% maturity. A Cox proportional hazards model was used to assess biomarker status by randomly assigned treatment interactions for progression-free survival (PFS) and OS.

Results

OS (954 deaths) was similar for gefitinib and carboplatin/paclitaxel with no significant difference between treatments overall (hazard ratio [HR], 0.90; 95% CI, 0.79 to 1.02; $P = .109$) or in *EGFR* mutation-positive (HR, 1.00; 95% CI, 0.76 to 1.33; $P = .990$) or *EGFR* mutation-negative (HR, 1.18; 95% CI, 0.86 to 1.63; $P = .309$; treatment by *EGFR* mutation interaction $P = .480$) subgroups. A high proportion (64.3%) of *EGFR* mutation-positive patients randomly assigned to carboplatin/paclitaxel received subsequent EGFR tyrosine kinase inhibitors. PFS was significantly longer with gefitinib for patients whose tumors had both high *EGFR* gene copy number and *EGFR* mutation (HR, 0.48; 95% CI, 0.34 to 0.67) but significantly shorter when high *EGFR* gene copy number was not accompanied by *EGFR* mutation (HR, 3.85; 95% CI, 2.09 to 7.09).

Conclusion

EGFR mutations are the strongest predictive biomarker for PFS and tumor response to first-line gefitinib versus carboplatin/paclitaxel. The predictive value of *EGFR* gene copy number was driven by coexisting *EGFR* mutation (post hoc analysis). Treatment-related differences observed for PFS in the *EGFR* mutation-positive subgroup were not apparent for OS. OS results were likely confounded by the high proportion of patients crossing over to the alternative treatment.

J Clin Oncol 29:2866-2874. © 2011 by American Society of Clinical Oncology

INTRODUCTION

The epidermal growth factor receptor (EGFR) represents an important signaling pathway that regulates tumorigenesis and cell survival and is frequently overexpressed in the development and pro-

gression of non-small-cell lung cancer (NSCLC).¹⁻⁴ EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib (Iressa, AstraZeneca, Macclesfield, United Kingdom) are effective in the treatment of relapsed NSCLC,^{5,6} with certain clinical subgroups deriving greater clinical benefit (adenocarcinoma histology,

From the Kinki University School of Medicine; AstraZeneca, Osaka, Japan; Guangdong General Hospital, Guangzhou; Cancer Hospital, Chinese Academy of Medical Sciences, Beijing; State Key Laboratory in Oncology in South China, Li Ka Shing Institute of Health Science and the Sir Y.K. Pao Center for Cancer, The Chinese University of Hong Kong, Hong Kong, China; Maharak Nakorn ChiangMai Hospital, ChiangMai University, ChiangMai; Prince of Songkla University, Songkla; Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; National Cancer Centre Singapore, Singapore; Tri-Service General Hospital; National Taiwan University Hospital and College of Medicine, Taipei, Taiwan; and AstraZeneca, Macclesfield, United Kingdom.

Submitted November 1, 2010; accepted February 14, 2011; published online ahead of print at www.jco.org on June 13, 2011.

Supported by AstraZeneca.

Presented in part at the 45th Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2009, Orlando, FL; at the 13th World Conference on Lung Cancer, July 31-August 4, 2009, San Francisco, CA; and at the 35th European Society for Medical Oncology Congress, October 8-12, 2010, Milan, Italy.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical Trials repository link available on JCO.org.

Corresponding author: Tony S.K. Mok, MD, The Chinese University of Hong Kong, 22D Union Court, 18 Fu Kin Street, Shatin, Hong Kong, China; e-mail: tony@clo.cuhk.edu.hk.

© 2011 by American Society of Clinical Oncology

0732-183X/11/2921-2866/\$20.00

DOI: 10.1200/JCO.2010.33.4235




Fig 1. CONSORT diagram. (*) Among the 112 patients who failed screening, the main reasons for exclusion were abnormal serum creatinine ($> 1.5 \times$ upper limit of reference range)/creatinine clearance (≤ 60 mL/min) levels; untreated CNS metastases; or low neutrophil ($< 2.0 \times 10^9/L$), platelet ($< 100 \times 10^9/L$), or hemoglobin (< 10 g/dL) counts. (†) Cutoff dates: June 14, 2010, for overall survival (OS) and April 14, 2008, for progression-free survival (PFS). (‡) All patients who were randomly assigned to a study group were included in the intent-to-treat (ITT) analysis. (§) Patients who did not deviate substantially from the inclusion and exclusion criteria at entry or from the protocol were included in the per-protocol analysis. (¶) All patients who received at least one dose of study treatment were included in the safety analysis. (#) All patients with a baseline and at least one postbaseline quality-of-life assessment that could be evaluated were included in the quality-of-life analysis. (*) All patients in the ITT population with an evaluable tumor sample. Of 683 patients (56%) who provided samples, 118 were cytology samples, and 128 were histologic samples of insufficient quality and were therefore not included in the main analysis. DCO, data cutoff; EGFR, epidermal growth factor receptor.

Asian ethnicity, female sex, and never-smoker status).⁵⁻⁷ These subgroups are associated with a higher incidence of activating somatic mutations of the *EGFR* gene.⁸⁻¹⁰ Optimization of anti-EGFR therapy depends on patient selection, and the exploration and identification of predictive biomarkers is important.

EGFR mutations, *EGFR* gene copy number, and EGFR protein expression are three EGFR-related biomarkers that have been studied in major clinical trials.¹¹⁻¹⁴ The significant overlap between EGFR biomarkers and limited availability of tumor samples in some studies made the interpretation of their individual predictive and prognostic values difficult.

Prolonged progression-free survival (PFS) and higher objective response rate (ORR) have been reported in patients with high *EGFR* gene copy number in single-arm and placebo-controlled randomized studies.^{12,15-17} However, in the large phase III, randomized Iressa NSCLC Trial Evaluating Response and Survival Versus Taxotere (INTEREST) study with an active comparator, high *EGFR* gene copy

number was not predictive for differential survival between gefitinib and docetaxel in patients with advanced NSCLC.¹⁸

The Iressa Pan-Asia Study (IPASS) is a phase III, randomized study of gefitinib versus carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma in East Asia. As previously reported, IPASS exceeded its primary objective of noninferiority, demonstrating superiority of gefitinib relative to carboplatin/paclitaxel for PFS in this clinically selected population.¹⁹ The treatment effect was not constant over time, driven by different outcomes according to mutation status. In the subgroup of patients with *EGFR* mutation-positive tumors, PFS was significantly longer for gefitinib versus carboplatin/paclitaxel (hazard ratio [HR], 0.48; 95% CI, 0.36 to 0.64; $P < .001$; median PFS, 9.5 v 6.3 months). Conversely, carboplatin/paclitaxel was superior in the *EGFR* mutation-negative subgroup (HR, 2.85; 95% CI, 2.05 to 3.98; $P < .001$; median PFS, 5.5 v 1.5 months); similarly, ORR significantly favored gefitinib and carboplatin/paclitaxel in the *EGFR* mutation-

Table 1. Summary of All Systemic Treatment After Discontinuation of Randomly Assigned Treatment in the Overall Population and in *EGFR* Mutation Subgroups (ITT population; data from OS data cutoff)

Treatment	Overall Population				<i>EGFR</i> Mutation Positive				<i>EGFR</i> Mutation Negative				<i>EGFR</i> Mutation Unknown			
	G (n = 609)		C/P (n = 606)		G (n = 132)		C/P (n = 129)		G (n = 91)		C/P (n = 85)		G (n = 386)		C/P (n = 394)	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Still on study treatment	20	3.3	0	0	3	2.3	0	0	1	1.1	0	0	16	4.1	0	0
None	190	31.2	230	37.8	29	22.0	37	28.7	21	23.1	25	29.4	140	36.3	168	42.6
Chemotherapy	393	64.5	251	41.3	99	75.0	61	47.3	69	75.8	44	51.8	225	58.3	146	37.1
Platinum-based†‡	363	59.6	55	9.0	90	68.2	13	10.1	65	71.4	10	11.8	208	53.9	32	8.1
C/P†‡	301	49.4	3	0.5	72	54.5	0	0	52	57.1	0	0	177	45.9	3	0.8
<i>EGFR</i> TKI	119	19.5	313	51.5	34	25.8	83	64.3	13	14.3	43	50.6	72	18.7	187	47.5
Gefitinib*†§	29	4.8	250	41.1	6	4.5	61	47.3	4	4.4	33	38.8	19	4.9	156	39.6
Erlotinib†§	71	11.7	83	13.7	16	12.1	31	24.0	9	9.9	7	8.2	46	11.9	45	11.4
Other <i>EGFR</i> TKI†§	33	5.4	35	5.8	15	11.4	12	9.3	2	2.2	5	5.9	16	4.1	18	4.6

NOTE. A patient may appear in more than one post-discontinuation treatment group. Patients may have received the same first- and second-line therapy. "None" is defined as patients who did not receive any form of cancer treatment after discontinuation of randomly assigned treatment. Radiotherapy, surgery, medical procedures, and other treatments were excluded.

Abbreviations: *EGFR*, epidermal growth factor receptor; ITT, intent-to-treat; OS, overall survival; G, gefitinib; C/P, carboplatin/paclitaxel; TKI, tyrosine kinase inhibitor. *Non-study medication after discontinuation of randomly assigned study treatment.

†Patients may have also received other chemotherapy and/or *EGFR* TKIs during the study.

‡Excludes single platinum-based chemotherapy.

§Patients may have had more than one type of *EGFR* TKI and are counted once for each type received.

positive and *EGFR* mutation-negative subgroups, respectively.¹⁹ A total of 1,038 of 1,217 patients consented to the preplanned exploratory biomarker analyses; 683 patients provided samples.

Early analysis of survival data (37% maturity) was presented in 2008.¹⁹ Here we present the final results of the survival analyses and the results of the preplanned and post hoc analyses of the relationships between *EGFR* biomarkers (*EGFR* mutation, *EGFR* gene copy number, and *EGFR* protein expression) and clinical outcomes from IPASS.

PATIENTS AND METHODS

Study Design and Treatment

Full details of IPASS have been published previously.¹⁹ Eligible patients had stage IIIB to IV pulmonary adenocarcinoma (including bronchoalveolar carcinoma), were either never-smokers (< 100 cigarettes in their lifetime) or light ex-smokers (stopped smoking \geq 15 years previously and smoked \leq 10 pack-years), and had received no prior chemotherapy or biologic or immunologic therapy.

Patients were randomly assigned 1:1 to gefitinib (250 mg/d) or carboplatin/paclitaxel (Paraplatin/Taxol, Bristol-Myers Squibb, Princeton, NJ; paclitaxel 200 mg/m² was given intravenously over 3 hours on day 1, immediately followed by carboplatin area under the serum concentration-time curve [AUC] 5.0 or 6.0 intravenously over 15 to 60 minutes in once every 3 weeks cycles for \leq six cycles).

The primary objective of IPASS was noninferiority of gefitinib relative to carboplatin/paclitaxel in terms of PFS. ORR and overall survival (OS) were secondary end points. Evaluation of biomarker status (*EGFR* mutation, gene copy number, and protein expression) and efficacy of gefitinib versus carboplatin/paclitaxel were preplanned exploratory objectives. Post hoc analyses included clinical outcomes according to *EGFR* mutation subtype, *EGFR* gene copy number by *EGFR* mutation status, and clinical outcomes for patients with tumor *EGFR* gene high polysomy, and *EGFR* gene amplification. Correlation between *EGFR* mutation status and *EGFR* gene copy number was also investigated.

Patients provided written, informed consent with separate consent obtained for optional provision of tumor material for biomarker analyses. Study approval was obtained from independent ethics committees at each institution. The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization/Good Clinical Practice, applicable regulatory requirements, and AstraZeneca's policy on bioethics.

Biomarker Analyses

Biomarker status was determined by analyzing paraffin-embedded archival tumor tissue in the following priority order: (1) *EGFR* mutation status, (2) *EGFR* gene copy number, (3) *EGFR* protein expression. Analyses were conducted at two central laboratories (Genzyme, Framingham, MA, and Quintiles-Lab in association with Peking Union Medical College Hospital, Beijing, China); scientists were blinded to clinical outcome and randomly assigned treatment. Samples underwent central histopathologic review; only those considered suitable for downstream biomarker analysis were progressed (on the basis of quality, sample source, and tumor content). If a patient provided more than one sample, the appropriate section was selected before database lock and analyzed on the basis of sample quality and largest area of tumor tissue.²⁰

EGFR mutations were detected by using an amplification mutation refractory system with an *EGFR* mutation detection kit (DxS, Manchester, United Kingdom).^{21,22} Patients were considered *EGFR* mutation positive if at least one of 29 *EGFR* mutations (Data Supplement) was detected. Additional validation for samples with T790M mutations was performed by using three methods: DNA sequencing, multithreaded electronic polymerase chain reaction sequencing, and an alternative amplification mutation refractory system assay (Data Supplement). *EGFR* gene copy number was measured by using fluorescent in situ hybridization and a previously published methodology.¹⁵ High *EGFR* gene copy number was defined according to the University of Colorado Scoring System, which included both high polysomy (\geq four copies in \geq 40% of cells; score 5) or gene amplification (presence of tight *EGFR* gene clusters and a ratio of gene/chromosome per cell $>$ two, or $>$ 15 copies of *EGFR* per cell in \geq 10% of analyzed cells; score 6).¹⁵ *EGFR* protein expression was assessed by immunohistochemistry by using the DAKO *EGFR* pharmDx kit (Dako, Glostrup, Denmark). Positive *EGFR* protein expression status was defined as having \geq 10% of cells stained.

Statistical Analyses

The study statistician performed the statistical analyses at AstraZeneca. In the overall population and clinical subgroups, OS was analyzed by using a Cox proportional hazards model adjusted for the same covariates as for the primary PFS analysis (WHO performance status, 0 to 1 v 2; smoking history, never-smoker v light ex-smoker; and sex, female v male). The HR (gefitinib: carboplatin/paclitaxel) was estimated with 95% CIs and *P* values. Final analysis of OS was planned for when 944 deaths (78%) had occurred in the intent-to-treat (ITT) population, the same level of maturity as for PFS.




Fig 2. Kaplan-Meier curves for overall survival (OS) in the overall population and by epidermal growth factor receptor (*EGFR*) mutation status (intent-to-treat population). Hazard ratio (HR) < 1 implies a lower risk of death for patients treated with gefitinib. Cox analysis with covariates (performance status [0-1, 2], smoking history [never, light ex-smoker], and sex). (A) Overall population. (B) Patients with *EGFR* mutation-positive tumors. (C) Patients with *EGFR* mutation-negative tumors. (D) Patients with *EGFR* mutation status unknown tumors.

For each biomarker, patients were classified as positive, negative, or unknown. For each of these groups, HRs, 95% CIs, and *P* values were estimated for PFS and OS (by using a Cox proportional hazards model adjusted for the same covariates as for the primary PFS analysis in the ITT population). The biomarker status by randomly assigned treatment interaction was assessed individually for each biomarker for PFS and OS by using a Cox proportional hazards model adjusted for randomly assigned treatment, biomarker status (positive or negative), and the biomarker status by treatment interaction by using a 10% significance level to indicate potential predictive factors for gefitinib versus carboplatin/paclitaxel. When there were fewer than 20 events in a subgroup for PFS or OS, only descriptive summaries were produced. Odds ratios, 95% CIs, and *P* values were estimated for ORRs by using a logistic regression model adjusted for the same covariates as those used in the analysis of PFS in the ITT population.

RESULTS

Patients

Patient disposition is presented in Figure 1. Therapies received postdiscontinuation of randomly assigned treatment are listed in Ta-

ble 1. Specifically, 83 (64.3%) of 129 patients with *EGFR* mutation-positive tumors randomly assigned to carboplatin/paclitaxel received subsequent EGFR TKIs.

OS (ITT Population)

The median duration of follow-up for OS was 17.0 months. At the time of data cutoff for OS (June 14, 2010), 954 patients (78%) had died (Fig 2A). In the overall population, OS was similar for gefitinib and carboplatin/paclitaxel with no significant difference between treatments (484 and 470 events, respectively; HR, 0.90; 95% CI, 0.79 to 1.02; *P* = .109; median OS for gefitinib, 18.8 months v 17.4 months for carboplatin/paclitaxel; Fig 2A). A consistent treatment effect was seen across all clinical subgroups (Fig 3C).

Biomarker Evaluations

Of 683 randomly assigned patients (56.1%) who provided samples for biomarker analysis, 118 were cytology samples, which were not included in the main analysis. The number of patients with an evaluable status was 437 (35.9%) for *EGFR* mutation, 406 (33.4%) for




Fig 3. Forest plot of progression-free survival (PFS) and overall survival (OS) by epidermal growth factor receptor (EGFR) mutation status, gene copy number, and protein expression status (intent-to-treat population). (A) PFS by biomarker status. (B) OS by biomarker status. (C) OS by clinical subgroup. Hazard ratio < 1 implies a lower risk of progression or death for patients treated with gefitinib. The size of the point estimate reflects the number of events in the subgroup, with a larger circle indicating more events. Cox analysis with covariates (performance status [PS], 0 to 1 or 2; smoking history, never-smoker, light ex-smoker; and sex). OS by biomarker status; no formal adjustment for multiple testing was made, therefore, statistical significance at the traditional 5% level (95% CI < 1) cannot be claimed. Protocolled interaction tests were calculated only for OS and clinical subgroups if there was a significant interaction test for PFS. NC, not calculated.

EGFR gene copy number, and 365 (30.0%) for EGFR protein expression (Fig 1); the percentage of patients with a positive EGFR biomarker status was 59.7% (261 of 437), 61.3% (249 of 406), and 72.9% (266 of 365), respectively. A summary of EGFR biomarker status is presented in the Data Supplement.

The demographics, baseline characteristics, and efficacy results of patients with evaluable samples for assessment of EGFR mutation status, gene copy number, and protein expression were generally comparable with the ITT population (Table 2). There was a high degree of overlap between patients who were positive for all three biomarkers; 190 patients (78.5%) with high EGFR gene copy number also harbored an EGFR mutation; 132 patients were positive for all three biomarkers.

EGFR Mutation Status

Demographic and baseline characteristics by EGFR mutation status are shown in the Data Supplement. PFS results by EGFR mutation status have been previously published¹⁹ (Fig 3A).

There was no differential treatment effect for OS by EGFR mutation (treatment by EGFR mutation interaction test $P = .480$). There was no significant difference in OS for gefitinib versus car-

boplatin/paclitaxel in the subgroups of patients with EGFR mutation-positive tumors (104 and 95 events, respectively; HR, 1.00; 95% CI, 0.76 to 1.33; $P = .990$; median OS, 21.6 v 21.9 months); EGFR mutation-negative tumors (82 and 74 events, respectively; HR, 1.18; 95% CI, 0.86 to 1.63; $P = .309$; median OS, 11.2 v 12.7 months), or mutation status unknown tumors (298 and 301 events, respectively; HR, 0.82; 95% CI, 0.70 to 0.96; $P = .015$; Figs 2B, 2C, 2D, and 3B). Postdiscontinuation treatments by EGFR mutation status are listed in Table 1.

EGFR Gene Copy Number

EGFR gene copy number was a predictive biomarker for the effect of gefitinib compared with carboplatin/paclitaxel on PFS (treatment by EGFR gene copy number interaction test $P = .044$; Fig 3A). In patients with high EGFR gene copy number (fluorescent in situ hybridization scores 5 and 6; $n = 249$), PFS was significantly longer with gefitinib versus carboplatin/paclitaxel (HR, 0.66; 95% CI, 0.50 to 0.88; $P = .005$). ORR also significantly favored gefitinib in these patients (58.9% v 44.8% for gefitinib v carboplatin/paclitaxel, respectively; odds ratio [OR], 1.79; 95% CI, 1.08 to 2.96; $P = .024$). Conversely, in

Table 2. Demographics, Baseline Characteristics, and Analysis Outcomes for Patients with Evaluable Tissue Samples for Each Biomarker Compared With the ITT Population

Variable	Evaluable for EGFR Mutation Status* (n = 437)					Evaluable for EGFR Gene Copy Number Status* (n = 406)					Evaluable for EGFR Protein Expression Status* (n = 365)					ITT Population (n = 1,217)					
	No.	%	HR	OR	95% CI	No.	%	HR	OR	95% CI	No.	%	HR	OR	95% CI	No.	%	HR	OR	95% CI	
Demographic characteristic																					
Female	335	76.7				313	77.1				285	78.1				965	79.3				
Age < 65 years	326	74.6				303	74.6				262	71.8				899	73.9				
WHO PS 0 or 1	402	92.0				375	92.4				334	91.5				1,091	89.6				
Never-smoker	405	92.7				375	92.4				334	91.5				1,140	93.7				
Locally advanced	83	19.0				77	19.0				67	18.4				295	24.2				
Efficacy																					
PFS			0.85		0.69 to 1.06			0.83		0.66 to 1.03			0.79		0.62 to 0.99			0.74		0.65 to 0.85	
ORR				1.21	0.83 to 1.78				1.31	0.88 to 1.95				1.43	0.94 to 2.18				1.59	1.25 to 2.01	
OS			1.05		0.85 to 1.29			1.10		0.89 to 1.37			1.04		0.82 to 1.30			0.90		0.79 to 1.02	

NOTE. Hazard ratio (HR) < 1 implies a lower risk of progression or death on gefitinib; odds ratio (OR) > 1 implies a greater chance of response on gefitinib. Abbreviations: ITT, intent to treat; EGFR, epidermal growth factor receptor; PS, performance status; PFS, progression-free survival; ORR, objective response rate; OS, overall survival.
*Irrespective of whether positive or negative for each biomarker.

patients with low EGFR gene copy number (n = 157), PFS was numerically longer (HR, 1.24; 95% CI, 0.87 to 1.76; P = .237) and ORR was numerically higher (26.3% v 22.2%; OR, 0.80; 95% CI, 0.38 to 1.68; P = .558) with carboplatin/paclitaxel versus gefitinib.

A total of 190 patients (78%) with high EGFR gene copy number also harbored EGFR mutations. Of the 153 patients with low EGFR gene copy number, only 51 (33%) were also EGFR mutation positive. Post hoc analyses found that PFS was significantly shorter with gefitinib versus carboplatin/paclitaxel in patients with high EGFR gene copy number in the absence of a coexisting EGFR mutation (n = 55; HR, 3.85; 95% CI, 2.09 to 7.09), although patients with EGFR mutation achieved significantly longer PFS with gefitinib versus carboplatin/paclitaxel irrespective of whether they had high (HR, 0.48; 95% CI, 0.34 to 0.67; n = 190) or low (HR, 0.51; 95% CI, 0.25 to 1.04; n = 51) EGFR gene copy number (Figs 4A to 4D).

There was no differential treatment effect for OS by EGFR gene copy number (treatment by EGFR gene copy number interaction test P = .428). There was no significant difference in OS for gefitinib versus carboplatin/paclitaxel in patients with high EGFR gene copy number (104 and 95 events, respectively; HR, 1.03; 95% CI, 0.78 to 1.37; P = .816) or low EGFR gene copy number (67 and 62 events, respectively; HR, 1.30; 95% CI, 0.92 to 1.85; P = .137; Fig 3B).

EGFR Protein Expression

There was no differential treatment effect for PFS by EGFR protein expression (treatment by EGFR protein expression status interaction test P = .214; Fig 3A). PFS was significantly longer for gefitinib versus carboplatin/paclitaxel in patients with EGFR protein expression-positive tumors (HR, 0.73; 95% CI, 0.55 to 0.96; P = .024; n = 266). There was no significant difference in PFS between treatments in patients with EGFR protein expression-negative tumors (HR, 0.97; 95% CI, 0.64 to 1.48; P = .893; n = 99).

ORRs were similar between the gefitinib and carboplatin/paclitaxel groups for patients with either EGFR protein expression-positive (51.5% v 41.8%; OR, 1.49; 95% CI, 0.92 to 2.42; P = .109) or EGFR protein expression-negative (34.0% v 26.1%; OR, 1.44; 95% CI, 0.60 to 3.47; P = .415) tumors.

There was no significant difference in OS for gefitinib versus carboplatin/paclitaxel in patients with EGFR protein expression-

positive (107 and 105 events, respectively; HR, 1.05; 95% CI, 0.80 to 1.37; P = .731) or EGFR protein expression-negative (46 and 37 events, respectively; HR, 1.09; 95% CI, 0.70 to 1.70; P = .692) tumors.

Activating EGFR Mutation Type

Of the 261 patients with EGFR mutation-positive tumors, 53.6% (n = 140) had tumors with exon 19 deletions, and 42.5% (n = 111) had exon 21 L858R mutations (Data Supplement); demography was generally similar between these groups (Data Supplement).

In post hoc analyses, PFS was significantly longer for gefitinib versus carboplatin/paclitaxel in both the exon 19 deletions (HR, 0.38; 95% CI, 0.26 to 0.56) and the exon 21 L858R mutation (HR, 0.55; 95% CI, 0.35 to 0.87; Figs 5A and 5B) subgroups. Within-treatment analysis indicated no significant difference in PFS with gefitinib in the exon 19 deletions versus exon 21 L858R mutation subgroup (HR, 0.78; 95% CI, 0.51 to 1.19). ORR was significantly higher with gefitinib (84.8%) versus carboplatin/paclitaxel (43.2%; OR, 7.23; 95% CI, 3.19 to 16.37) in the exon 19 deletions subgroup and higher (but not statistically significant) in the L858R subgroup (60.9% v 53.2%; OR, 1.41; 95% CI, 0.65 to 3.05).

DISCUSSION

Gefitinib showed similar OS to doublet chemotherapy with no significant difference in the overall population or in patients with EGFR mutation-positive or EGFR mutation-negative status. The significant treatment-related differences for PFS and ORR according to EGFR mutation status were not observed for OS. Although there may be other contributing factors, the subsequent treatments that patients received are likely to have confounded the true effect of the initial, randomized first-line treatment on OS. Of the EGFR mutation-positive subgroup randomly assigned to carboplatin/paclitaxel, 64.3% received EGFR TKIs postdiscontinuation. Fewer patients with unknown mutation status randomly assigned to carboplatin/paclitaxel received EGFR TKIs (47.5%) compared with patients with EGFR mutation-positive status (64.3%), which may potentially contribute to the numerical trend in favor of gefitinib in this subgroup; statistical significance at the traditional 5% level (P < .05) cannot be claimed because no adjustment was made for multiple testing. The First-SIGNAL study had a study design similar to that of IPASS²³ and




Fig 4. Kaplan-Meier curves for progression-free survival (PFS) by epidermal growth factor receptor (*EGFR*) mutation status and *EGFR* gene copy number. Hazard ratio (HR) < 1 implies a lower risk of progression/death for patients treated with gefitinib. (A) High *EGFR* gene copy number *EGFR* mutation-positive. (B) High *EGFR* gene copy number *EGFR* mutation-negative. (C) Low *EGFR* gene copy number *EGFR* mutation-positive. (D) Low *EGFR* gene copy number *EGFR* mutation-negative. (*) Cox analysis with covariates (performance status [0-1, 2], smoking history [never, light ex-smoker], and sex).

reported no significant difference in OS (primary end point) between gefitinib versus gemcitabine/cisplatin (overall population, 182 events; 59% maturity; mutation-positive HR, 0.82; 95% CI, 0.35 to 1.92; $P = .648$; median survival, 30.6 v 26.5 months, respectively). The randomized Japanese NEJ002 study also reported that OS did not differ significantly between gefitinib and carboplatin/paclitaxel in patients selected by *EGFR* mutation status (median survival, 30.5 v 23.6 months, respectively; $P = .31$), likely explained by treatment crossover.²⁴

Although collection of tumor material was not mandatory or feasible in all patients, IPASS has the largest group of patients with *EGFR* mutation-positive tumors studied in a randomized controlled trial in NSCLC and has confirmed *EGFR* mutation to be the strongest predictive biomarker for the effect of gefitinib with a statistically significant interaction test for PFS. Patients with mutation-negative tumors have a poorer outcome in terms of PFS and ORR with gefitinib compared with carboplatin/paclitaxel, indicating that in the first-line setting, gefitinib should not be used in preference to doublet chemotherapy in patients with a negative mutation status.

Our findings were broadly consistent with those of previous first-line, single-arm studies of gefitinib in patients with *EGFR*

mutation-positive tumors.²⁵⁻³² Recently, outcomes similar to those of IPASS among patients with *EGFR* mutation-positive tumors have been reported in two randomized phase III studies^{24,33} comparing first-line gefitinib with doublet chemotherapy, with PFS as the primary end point. The NEJ002 study prospectively randomly assigned 230 patients with *EGFR* mutation-positive tumors to gefitinib or carboplatin/paclitaxel. PFS favored gefitinib over carboplatin/paclitaxel (PFS HR, 0.30; 95% CI, 0.22 to 0.41; $P < .001$; median PFS, 10.8 v 5.4 months; tumor response rate, 73.7% v 30.7%, respectively; $P < .001$).²⁴ The similarly designed West Japan Thoracic Oncology Group 3405 (WJTOG3405) study reported increased PFS with gefitinib over cisplatin/docetaxel in 172 patients with *EGFR* mutation-positive tumors (PFS HR, 0.49; 95% CI, 0.34 to 0.70; $P < .001$; median PFS, 9.2 v 6.3 months; 295 events; 95% maturity).³³ Tumor response rates ($n = 117$) were 62.1% and 32.2%. In the First-SIGNAL study, PFS (secondary end point) increased with gefitinib compared with gemcitabine/cisplatin in 42 patients with *EGFR* mutation-positive tumors (PFS HR, 0.61; 95% CI, 0.31 to 1.22; $P = .084$; median PFS, 8.4 v 6.7 months).²³ The OPTIMAL study compared erlotinib with gemcitabine/cisplatin in 154 patients with *EGFR* mutation-positive tumors and also reported a significant difference in PFS (HR, 0.16; 95% CI, 0.10 to 0.26; $P = .001$).³⁴ The similarly designed European Tarceva




Fig 5. Kaplan-Meier curves for progression-free survival (PFS) by epidermal growth factor receptor (*EGFR*) mutation type (intent-to-treat population). Hazard ratio (HR) < 1 implies a lower risk of progression/death for patients treated with gefitinib. (A) Exon 19 deletion. (B) L858R. (*) Cox analysis with covariates (performance status [0-1, 2], smoking history [never, light ex-smoker], and sex).

versus Chemotherapy (EURTAC) study is ongoing. Therefore to date, including IPASS, five randomized studies have shown that *EGFR* TKIs offer significant benefits over standard chemotherapy in patients with *EGFR* mutation-positive tumors.

In IPASS, high *EGFR* gene copy number was predictive for the effect of gefitinib versus carboplatin/paclitaxel on PFS. The significantly longer PFS with gefitinib in patients with both high *EGFR* gene copy number and *EGFR* mutation-positive tumors was not observed in patients with high *EGFR* gene copy number without an accompanying mutation, suggesting that the apparent PFS benefit was driven by overlap with a coexisting *EGFR* mutation (77.6% of patients with high *EGFR* gene copy number also had *EGFR* mutation-positive tumors). Patients with *EGFR* mutation-positive tumors without accompanying high *EGFR* gene copy number showed longer PFS with gefitinib than with carboplatin/paclitaxel, suggesting that *EGFR* mutations determine the treatment outcomes independent of the status of *EGFR* gene copy number.

Post hoc analyses of PFS by *EGFR* mutation type showed that PFS was significantly longer for gefitinib than for carboplatin/paclitaxel in both the exon 19 deletions and exon 21 L858R subgroups, with a slightly greater advantage in the exon 19 deletions subgroup. First-line, single-arm studies^{35,36} have reported an increased response to *EGFR* TKIs in patients with exon 19 deletions *v* exon 21 L858R mutation. However, IPASS (HR, 0.78; 95% CI, 0.51 to 1.19), WJTOG3405 (HR, 1.13; 95% CI, 0.63 to 2.03; $P = .681$), and NEJ002 (11.5 *v* 10.8 months; $P = .90$) randomized phase III studies and the prospective phase II iTARGET study ($P = .600$) showed no significant difference in PFS for gefitinib between the exon 19 deletions and exon 21 L858R mutation subgroups.^{24,25,33}

In summary, *EGFR* mutation was the strongest predictive biomarker for benefit of gefitinib over carboplatin/paclitaxel on PFS and ORR. Post hoc analyses suggested that the predictive value of *EGFR* gene copy number for PFS benefit with gefitinib was driven by the overlap of high *EGFR* gene copy number with a positive *EGFR* mutation status. Treatment-related differences for PFS seen in patients with a positive *EGFR* mutation status were not apparent for OS. The OS results were likely confounded by the high proportion of patients receiving different types of subsequent therapies and, in particular, crossing over to the alternative treatment.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: Emma L. Duffield, AstraZeneca (C); Yuri Rukazekov, AstraZeneca (C); Georgina Speake, AstraZeneca (C); Haiyi Jiang, AstraZeneca (C); Alison A. Armour, AstraZeneca (C) **Consultant or Advisory Role:** Sumitra Thongprasert, AstraZeneca (C), Novartis (C), Pfizer (C); Swan-Swan Leong, AstraZeneca (C); James Chih-Hsin Yang, AstraZeneca (C); Tony S.K. Mok, AstraZeneca (C), Roche (C), Pfizer (C), Bristol-Myers Squibb (C), Abbott Laboratories (C), Eli Lilly (C), Boehringer Ingelheim (C) **Stock Ownership:** Emma L. Duffield, AstraZeneca; Yuri Rukazekov, AstraZeneca; Georgina Speake, AstraZeneca; Haiyi Jiang, AstraZeneca; Alison A. Armour, AstraZeneca **Honoraria:** Masahiro Fukuoka, AstraZeneca, Chugai Pharmaceutical, Boehringer Ingelheim; Yi-Long Wu, AstraZeneca, Roche, Eli Lilly; Sumitra Thongprasert, AstraZeneca, Eli Lilly; Patrapim Sunpawaravong, AstraZeneca; Kazuhiko Nakagawa, AstraZeneca, Chugai Pharmaceutical, Bristol-Myers Squibb; Da-Tong Chu, AstraZeneca; Ka-Fai To, AstraZeneca; James Chih-Hsin Yang, AstraZeneca; Tony S.K. Mok, AstraZeneca, Roche, Eli Lilly, Pfizer, Boehringer Ingelheim, Eisai Pharmaceuticals **Research Funding:** Sumitra Thongprasert, AstraZeneca, Roche, Pfizer, sanofi-aventis; Patrapim Sunpawaravong, AstraZeneca; Tony S.K. Mok, AstraZeneca **Expert Testimony:** None **Other Remuneration:** Swan-Swan Leong, AstraZeneca

AUTHOR CONTRIBUTIONS

Conception and design: Masahiro Fukuoka, Sumitra Thongprasert, Nagahiro Saijo, Haiyi Jiang, Alison A. Armour, Ka-Fai To, James Chih-Hsin Yang, Tony S.K. Mok **Provision of study materials or patients:** Yi-Long Wu, Swan-Swan Leong, Virote Sriuranpong, Ka-Fai To **Collection and assembly of data:** Yi-Long Wu, Sumitra Thongprasert, Patrapim Sunpawaravong, Swan-Swan Leong, Virote Sriuranpong,

Tsu-Yi Chao, Da-Tong Chu, Yuri Rukazenzov, Haiyi Jiang, Alison A. Armour, James Chih-Hsin Yang, Tony S.K. Mok
Data analysis and interpretation: Sumitra Thongprasert, Kazuhiko Nakagawa, Emma L. Duffield, Yuri Rukazenzov, Georgina Speake,

Haiyi Jiang, Alison A. Armour, James Chih-Hsin Yang,
 Tony S.K. Mok
Manuscript writing: All authors
Final approval of manuscript: All authors

REFERENCES

- Sato M, Shames DS, Gazdar AF, et al: A translational view of the molecular pathogenesis of lung cancer. *J Thorac Oncol* 2:327-343, 2007
- Sun S, Schiller JH, Gazdar AF: Lung cancer in never smokers: A different disease. *Nat Rev Cancer* 7:778-790, 2007
- Tang X, Shigematsu H, Bekele BN, et al: EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. *Cancer Res* 65:7568-7572, 2005
- Bhutani M, Pathak AK, Fan YH, et al: Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. *Cancer Prev Res (Phila)* 1:39-44, 2008
- Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. *J Clin Oncol* 21:2237-2246, 2003
- Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. *JAMA* 290:2149-2158, 2003
- Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). *Lancet* 366:1527-1537, 2005
- Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 350:2129-2139, 2004
- Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. *Science* 304:1497-1500, 2004
- Mitsudomi T, Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. *Cancer Sci* 98:1817-1824, 2007
- Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer: Molecular and clinical predictors of outcome. *N Engl J Med* 353:133-144, 2005
- Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. *J Clin Oncol* 24:5034-5042, 2006
- Douillard JY, Shepherd FA, Hirsh V, et al: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial. *J Clin Oncol* 28:744-752, 2010
- Zhu CQ, da Cunha Santos G, Ding K, et al: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. *J Clin Oncol* 26:4268-4275, 2008
- Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. *J Natl Cancer Inst* 97:643-655, 2005
- Hirsch FR, Varella-Garcia M, McCoy J, et al: Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group study. *J Clin Oncol* 23:6838-6845, 2005
- Goss G, Ferry D, Wierzbicki R, et al: Randomized phase II study of gefitinib compared with placebo in chemotherapy-naïve patients with advanced non-small-cell lung cancer and poor performance status. *J Clin Oncol* 27:2253-2260, 2009
- Kim ES, Hirsh V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. *Lancet* 372:1809-1818, 2008
- Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 361:947-957, 2009
- McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies (REMARK). *J Natl Cancer Inst* 97:1180-1184, 2005
- Whitcombe D, Theaker J, Guy SP, et al: Detection of PCR products using self-probing amplicons and fluorescence. *Nat Biotechnol* 17:804-807, 1999
- Newton CR, Graham A, Heptinstall LE, et al: Analysis of any point mutation in DNA: The amplification refractory mutation system (ARMS). *Nucleic Acids Res* 17:2503-2516, 1989
- Lee JS, Park K, Kim SW, et al: A randomized phase III study of gefitinib (IRESSA™) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. *J Thorac Oncol* 4, 2009 (suppl 1; abstr PRS.4)
- Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 362:2380-2388, 2010
- Sequist LV, Martins RG, Spigel D, et al: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. *J Clin Oncol* 26:2442-2449, 2008
- Asahina H, Yamazaki K, Kinoshita I, et al: A phase II trial of gefitinib as first-line therapy for advanced non-small-cell lung cancer with epidermal growth factor receptor mutations. *Br J Cancer* 95:998-1004, 2006
- Inoue A, Suzuki T, Fukuhara T, et al: Prospective Phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. *J Clin Oncol* 24:3340-3346, 2006
- Sugio K, Uramoto H, Onitsuka T, et al: Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. *Lung Cancer* 64:314-318, 2009
- Sunaga N, Tomizawa Y, Yanagitani N, et al: Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small-cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. *Lung Cancer* 56:383-389, 2007
- Sutani A, Nagai Y, Udagawa K, et al: Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. *Br J Cancer* 95:1483-1489, 2006
- Tamura K, Okamoto I, Kashii T, et al: Multicentre prospective phase II trial of gefitinib for advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: Results of the West Japan Thoracic Oncology Group trial (WJTOG0403). *Br J Cancer* 98:907-914, 2008
- Yoshida K, Yatabe Y, Park JY, et al: Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. *J Thorac Oncol* 2:22-28, 2007
- Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. *Lancet Oncol* 11:121-128, 2010
- Zhou C, Wu YL, Chen G, et al: Efficacy results from the randomized phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib vs carboplatin plus gemcitabine in Chinese advanced NSCLC patients with EGFR activating mutations. *Ann Oncol* 21, 2010 (suppl 8; abstr LBA13)
- Yang CH, Yu CJ, Shih JY, et al: Specific EGFR mutations predict treatment outcome of stage III/IV patients with chemotherapy-naïve non-small-cell lung cancer receiving first-line gefitinib monotherapy. *J Clin Oncol* 26:2745-2753, 2008
- Rosell R, Moran T, Queralt C, et al: Screening for epidermal growth factor receptor mutations in lung cancer. *N Engl J Med* 361:958-967, 2009

Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study

Isamu Okamoto, Hiroshige Yoshioka, Satoshi Morita, Masahiko Ando, Koji Takeda, Takashi Seto, Nobuyuki Yamamoto, Hideo Saka, Kazuhiro Asami, Tomonori Hirashima, Shinzoh Kudoh, Miyako Satouchi, Norihiko Ikeda, Yasuo Iwamoto, Toshiyuki Sawa, Masaki Miyazaki, Kenji Tamura, Takayasu Kurata, Masahiro Fukuoka, and Kazuhiko Nakagawa

From the Kinki University Faculty of Medicine; Osaka City General Hospital; National Hospital Organization, Kinki-chuo Chest Medical Center; Osaka Prefectural Medical Center for Respiratory and Allergic Diseases; Osaka City University Medical School; Cancer Center, Izumi Municipal Hospital, Osaka; Kurashiki Central Hospital, Kurashiki; Yokohama City University Medical Center, Yokohama; Kyoto University School of Public Health, Kyoto; National Kyushu Cancer Center, Fukuoka; Shizuoka Cancer Center, Nagaizumi; National Hospital Organization, Nagoya Medical Center, Nagoya; Hyogo Cancer Center, Akashi; Tokyo Medical University, Tokyo; Hiroshima City Hospital, Hiroshima; Gifu Municipal Hospital, Gifu; and the Kinki University School of Medicine, Nara Hospital, Nara, Japan.

Submitted June 13, 2010; accepted September 24, 2010; published online ahead of print at www.jco.org on November 15, 2010.

Supported by Taiho Pharmaceutical Co Ltd.

Presented in part at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010.

This study is registered with University Hospital Medical Information Network Clinical Trial Registry (<http://www.umin.ac.jp/ctr/index.htm>, identification number UMIN00000503).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical Trials repository link available on JCO.org.

Corresponding author: Isamu Okamoto, MD, PhD, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan; e-mail: chi-okamoto@dotd.med.kindai.ac.jp.

© 2010 by American Society of Clinical Oncology

0732-183X/10/2836-5240/\$20.00

DOI: 10.1200/JCO.2010.31.0326

A B S T R A C T

Purpose

The primary goal of this open-label, multicenter, randomized phase III trial was to determine whether treatment with carboplatin plus the oral fluoropyrimidine derivative S-1 was noninferior versus that with carboplatin plus paclitaxel with regard to overall survival (OS) in chemotherapy-naïve patients with advanced non–small-cell lung cancer (NSCLC).

Patients and Methods

A total of 564 patients were randomly assigned to receive either carboplatin (area under the curve, 5) on day 1 plus oral S-1 (40 mg/m² twice per day) on days 1 to 14 or carboplatin (area under the curve, 6) plus paclitaxel (200 mg/m²) on day 1 every 21 days.

Results

At the planned interim analysis, with a total of 268 death events available, the study passed the O'Brien-Fleming boundary of 0.0080 for a positive result and noninferiority of carboplatin and S-1 compared with carboplatin and paclitaxel was confirmed for OS (hazard ratio, 0.928; 99.2% CI, 0.671 to 1.283). Median OS was 15.2 months in the carboplatin and S-1 arm and 13.3 months in the carboplatin and paclitaxel arm, with 1-year survival rates of 57.3% and 55.5%, respectively. Rates of leukopenia or neutropenia of grade 3/4, febrile neutropenia, alopecia, and neuropathy were more frequent in the carboplatin and paclitaxel arm, whereas thrombocytopenia, nausea, vomiting, and diarrhea were more common in the carboplatin and S-1 arm. The carboplatin and S-1 arm had significantly more dose delays than the carboplatin and paclitaxel arm.

Conclusion

Oral S-1 with carboplatin was noninferior in terms of OS compared with carboplatin and paclitaxel in patients with advanced NSCLC, and is thus a valid treatment option.

J Clin Oncol 28:5240-5246. © 2010 by American Society of Clinical Oncology

INTRODUCTION

Lung cancer is the leading cause of death related to cancer worldwide,¹ with non–small-cell lung cancer (NSCLC) accounting for 85% of lung cancer cases. For individuals with advanced or metastatic NSCLC, platinum-based chemotherapy is the mainstay of first-line treatment on the basis of the moderate improvement in survival and quality of life it affords compared with best supportive care alone.²⁻⁵ Thus, there is still a need for new treatment regimens to ameliorate symptoms and prolong survival in patients with advanced NSCLC in a manner that is both convenient and safe.

S-1 (TS-1; Taiho Pharmaceutical Co Ltd, Tokyo, Japan) is an oral fluoropyrimidine agent that

consists of tegafur, 5-chloro-2,4-dihydropyridine, and potassium oxonate in a molar ratio of 1:0.4:1.^{6,7} A phase II trial of oral S-1 as a single agent for the treatment of advanced NSCLC yielded a response rate of 22% and a median survival time of 10.2 months in 59 patients without prior chemotherapy.⁸ We previously performed a phase I/II study of carboplatin/S-1 combination therapy and found that administration of S-1 (40 mg/m² twice per day) on days 1 to 14 in combination with carboplatin (area under the curve [AUC], 5) on day 1 of every 3-week cycle yielded efficacy results similar to those of other platinum doublets.⁹ The carboplatin and S-1 combination had a more favorable toxicity profile than that typically seen with platinum-based regimens,

S-1 and Carboplatin v Paclitaxel and Carboplatin for NSCLC




Fig 1. CONSORT diagram for the study.

especially with regard to neutropenia, febrile neutropenia, neuropathy, and alopecia.⁹ In addition, replacement of paclitaxel with oral S-1 in combination therapy with carboplatin avoids the need for premedication to ameliorate paclitaxel-induced hypersensitivity and the 3-hour infusions required for paclitaxel administration. We therefore undertook and now report the results of the LETS (Lung Cancer Evaluation of TS-1) study, a multicenter, randomized, phase III, non-inferiority trial of carboplatin and S-1 in comparison with carboplatin and paclitaxel combination therapy in chemotherapy-naïve patients with advanced NSCLC.

PATIENTS AND METHODS

Patients

The criteria for patient eligibility included a diagnosis of NSCLC confirmed either histologically or cytologically; a clinical stage of IIIB not amena-

ble to curative treatment or of stage IV; a measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST)¹⁰; no prior chemotherapy; an age of 20 to 74 years; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; and a projected life expectancy of at least 3 months. Patients had adequate bone marrow reserve and organ function including a calculated creatinine clearance of ≥ 60 mL/min based on the standard Cockcroft and Gault formula. Radiation therapy for metastatic disease was permitted if it was completed at least 2 weeks before random assignment. Main exclusion criteria included active concomitant malignancy, symptomatic brain metastasis, interstitial pneumonia, watery diarrhea, heart failure, uncontrolled diabetes mellitus, active infection, and a past history of drug allergy. These inclusion and exclusion criteria are consistent with those of previous studies involving carboplatin and paclitaxel treatment.¹¹ Written informed consent was obtained from all patients, and the study protocol was approved by the institutional ethics committee of each of the participating institutions.

Treatment Plan

Eligible patients were randomly assigned to receive either carboplatin (AUC, 6) plus paclitaxel (200 mg/m²) on day 1¹¹ or carboplatin (AUC, 5) on day 1 plus oral S-1 (40 mg/m² twice per day) on days 1 to 14. Chemotherapy was repeated every 3 weeks for a maximum of six cycles unless there was earlier evidence of disease progression or intolerance of the study treatment.

End Points

The primary objective of this open-label, multicenter, randomized phase III trial was to establish the noninferiority of S-1 plus carboplatin compared with paclitaxel plus carboplatin as first-line therapy in terms of overall survival (OS) in patients with advanced NSCLC. Secondary end points included tumor response, treatment safety, quality of life (QOL), and progression-free survival (PFS).

Baseline and Follow-Up Assessments

Baseline evaluations included medical history, physical examination, ECG, tumor status, ECOG performance status, and laboratory analyses. During treatment, blood counts and biochemical tests were performed at least biweekly. A computed tomography scan was performed for tumor assessment within 14 days of initiation of study treatment and was repeated after every 1 to 2 months of planned therapy. All responses were defined according to RECIST. If a patient was documented as having a complete response (CR) or a

Table 1. Patient Demographic and Clinical Characteristics

Characteristic	Carboplatin/Paclitaxel (n = 281)		Carboplatin/S-1 (n = 282)		P
	No.	%	No.	%	
Age, years					
Median		63		64	.510
Range		36-74		38-74	
Sex					
Male	215	76.5	217	77.0	.902
Female	66	23.5	65	23.0	
ECOG PS					
0	90	32.0	86	30.5	.695
1	191	68.0	196	69.5	
Histology					
Adenocarcinoma	195	69.4	195	69.1	.560
Nonadenocarcinoma	86	30.6	87	30.9	
Clinical stage					
IIIB	68	24.2	68	24.1	.981
IV	213	75.8	214	75.9	
Smoking status					
Smoker	229	81.5	230	81.6	.984
Nonsmoker	52	18.5	52	18.4	

Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance status.

partial response (PR), a confirmatory evaluation was performed after an interval of 4 weeks. Disease control was defined as the best tumor response among CR, PR, or stable disease that was confirmed and sustained for 6 weeks or longer. Patients were evaluated for adverse events during therapy and until 42 days after administration of the last dose of the study treatment. Toxicity was evaluated according to the National Cancer Institute Cancer Common Toxicity Criteria, version 3. QOL was assessed with the lung cancer subscale of the Functional Assessment of Cancer Therapy–Lung (FACT-L)¹² and the neurotoxicity subscale of the FACT/Gynecology Oncology Group–Neurotoxicity (GOG-Ntx) version 4.¹³ In addition, alopecia was evaluated on the basis of the single item “I have been bothered by hair loss,” which was included in the former version of FACT-L. The maximum attainable scores on the lung cancer subscale, neurotoxicity subscale, and alopecia item were 28, 44, and 4, respectively, with which the patient was considered to be asymptomatic. Patients were asked to complete each instrument at the time of enrollment and at 6 and 9 weeks after initiation of treatment.

Statistical Analysis

Eligible patients were randomly assigned according to a 1:1 ratio to receive either carboplatin and paclitaxel or carboplatin and S-1. After a check of patient eligibility, random assignment was performed centrally at the West Japan Oncology Group data center by minimization with stratification factors including disease stage (IIIB v IV), type of histology (adenocarcinoma v nonadenocarcinoma), sex (male v female), and investigator center. The intent-to-treat (ITT) patient population included all patients who underwent random assignment. The per-protocol (PP) population was defined as the ITT population minus patients considered to have major violations of inclusion or exclusion criteria and those who did not receive any protocol treatment. The safety population was defined as all patients receiving at least one dose of study drugs. The primary end point of the study was OS, which was analyzed in the ITT population by estimation of the hazard ratio (HR) and two-sided 95% CI derived from a Cox regression model with adjustment for the stratification factors with the exception of investigator center. Median OS in both treatment arms was assumed to be 14 months on the basis of data from previous clinical trials.¹¹ Noninferiority of carboplatin and S-1 was to be concluded if the upper limit of the 95% CI of the HR was lower than 1.33; that is, the null hypothesis that the median OS of the carboplatin and S-1 group would be up to 3.48 months shorter than that of the carboplatin and paclitaxel group was analyzed. Demonstration of noninferiority with a statistical power of 85% at a two-sided significance level of .05 and 2 years of follow-up after 2.5 years of accrual would require 263 patients in each treatment group. Given the possibility of variance inflation due to censoring, the sample size was set at 560 (280 per arm). One interim analysis was planned when all the patients had been enrolled. For analysis of the primary end point, adjustment for multiple comparisons was handled by the method of Lan and DeMets, with the use of the O'Brien-Fleming type α spending function. The significance level was set at .008 for the interim analysis, taking the numbers of observed events ($n = 268$) and expected events ($n = 442$) into account. Survival curves (PFS and OS) were analyzed by the Kaplan-Meier method and were compared between groups by the Cox regression model. The 95% CI for median PFS and OS was calculated by the method of Brookmeyer and Crowley. Planned subgroup analyses for OS were performed to examine the interaction effect of treatment arm with each of performance status, sex, disease stage, type of histology, and smoking status. Patient characteristics (ie, sex, ECOG PS, histology, clinical stage, and smoking status) as well as response and toxicity incidence were compared between the two treatment arms by the χ^2 test, and age was compared by the Wilcoxon test. Longitudinal QOL data were analyzed with a linear mixed-effects model. All P values were two sided. Statistical analyses were performed with SAS for Windows, release 9.1 (SAS Institute, Cary, NC).

RESULTS

Patient Characteristics

From August 2006 to May 2008, 564 patients from 30 institutions were enrolled in the study. One patient was excluded from the carbo-

platin and paclitaxel arm because of loss to follow-up. The ITT population thus consisted of 563 patients: 281 individuals randomly assigned to the carboplatin and paclitaxel group and 282 individuals randomly assigned to the carboplatin and S-1 group (Fig 1). The baseline demographic and disease-related characteristics of the study subjects were well-balanced between the two treatment arms (Table 1). Two patients in the carboplatin and paclitaxel arm and three patients in the carboplatin and S-1 arm did not receive any chemotherapy, with the result that 558 patients were eligible for safety analysis (Fig 1).

Delivered Chemotherapy

The number of treatment courses administered was 1,037 in the carboplatin and paclitaxel arm (median, 4; range, 1 to 6) and 987 in the carboplatin and S-1 arm (median, 4; range, 1 to 6). Dose reductions occurred in 90 (8.7%) of the carboplatin and paclitaxel courses and in 49 (5.0%) of the carboplatin and S-1 courses. Carboplatin and paclitaxel dose reductions were mainly due to neuropathy, whereas those for carboplatin and S-1 were most commonly attributable to thrombocytopenia. Dose delays occurred in 47.9% of carboplatin and paclitaxel courses and 68.5% of carboplatin and S-1 courses. Delays due to




Fig 2. (A) Overall survival and (B) progression-free survival for the intent-to-treat population ($n = 563$). HR, hazard ratio.

S-1 and Carboplatin v Paclitaxel and Carboplatin for NSCLC




Fig 3. Subgroup analysis of overall survival in the intent-to-treat population (n = 563). PS, performance status; Adeno, adenocarcinoma; Nonadeno, nonadenocarcinoma.

hematologic toxicity occurred in a higher proportion of carboplatin and S-1 courses (51.6%) than carboplatin and paclitaxel courses (9.6%). S-1 was administered for the planned 14 days without interruption in 89.1% of carboplatin and S-1 courses. The median relative dose intensities were high for both carboplatin and paclitaxel (89.6% and 87.6%, respectively) and carboplatin and S-1 arms (83.3% and 94.3%, respectively). The most frequent reason for discontinuation of therapy was disease progression in both arms. Treatment was withdrawn before completion from a similar proportion of patients in each group (13.6% for carboplatin and paclitaxel and 10.7% for carboplatin and S-1) because of adverse events.

Efficacy

At the interim analysis planned for when patient enrollment was completed, 268 death events were available in total. The study passed the O'Brien-Fleming boundary of 0.0080 for a positive result with a *P* value of .002. The HR for OS (carboplatin and S-1 v carboplatin and paclitaxel) in the ITT population was 0.928, with a two-sided 99.2% CI after adjustment for multiplicity due to interim analysis of 0.671 to 1.283 (Fig 2A). Noninferiority of carboplatin and S-1 therapy was thus confirmed at the interim analysis by the upper limit of the CI being less than the protocol-specified margin of 1.33. The crude (unadjusted) 95% CI of the HR for OS of 0.928 was 0.730 to 1.179 in the ITT population, and an HR for OS of 0.931 (95% CI, 0.732 to 1.186) was obtained with the PP population. Median OS was 15.2 months (95% CI, 12.4 to 17.1) in the carboplatin and S-1 arm and 13.3 months (95% CI, 11.7 to 15.1) in the carboplatin and paclitaxel arm, with the 1-year survival rates being 57.3% and 55.5%, respectively. Subgroup analysis of OS in the ITT population according to stratification variables and other baseline characteristics were consistent with the primary analysis. A significant interaction effect between treatment arm and subgroups was not observed. The 95% CI for the HR in each subgroup included 1.00 (Fig 3).

The median PFS was 4.1 months in the carboplatin and S-1 arm and 4.8 months in the carboplatin and paclitaxel arm in the ITT population, with a corresponding HR of 0.998 and 95% CI of 0.837 to 1.190 (Fig 2B). In the PP population, the median values of PFS were 4.2 and 4.8 months for the carboplatin and S-1 and carboplatin and paclitaxel arms, respectively, with a corresponding HR of 0.992 and 95% CI of 0.832 to 1.184. Response to treatment was assessed in 279 patients (99.3%) of the carboplatin and paclitaxel group and in 279 patients (98.9%) of the carboplatin and S-1 group. For overall response (CR + PR) rate, carboplatin and paclitaxel was superior to carboplatin and S-1 (29.0% v 20.4%; *P* = .019, χ^2 test), whereas the overall disease control (CR + PR + stable disease) rate was similar in both treatment groups (73.5% v 71.7%, respectively; *P* = .635).

Safety

The incidence of leukopenia or neutropenia of grade 3 or 4 was significantly lower for patients in the carboplatin and S-1 arm than for those in the carboplatin and paclitaxel arm (leukopenia, 5% v 33%; neutropenia, 21% v 77%, respectively), as was the incidence of febrile neutropenia (1% v 7%; Table 2). Conversely, treatment with carboplatin and S-1 was associated with a higher rate of thrombocytopenia of grade 3 or 4 than was that with carboplatin and paclitaxel (33% v 9%, respectively). Platelet transfusion was also necessary for more patients in the carboplatin and S-1 arm than in the carboplatin and paclitaxel arm (8% v 2%, respectively; *P* = .002). The overall rates of neuropathy and alopecia were much lower in the carboplatin and S-1 arm (neuropathy, 16% v 81%; alopecia, 9% v 77%), whereas nausea, vomiting, and diarrhea occurred more frequently in the carboplatin/S-1 arm (Table 2). Death as a result of toxicity occurred in two patients; one death in the carboplatin and S-1 arm was associated with gastrointestinal hemorrhage, and another patient in the carboplatin and paclitaxel arm died of febrile neutropenia and pneumonia.

Table 2. Incidence of Drug-Related Toxicities in Randomly Assigned and Treated Patients

Toxicity	Regimen by Grade (%)						P	
	Carboplatin/Paclitaxel (n = 279)			Carboplatin/S-1 (n = 279)				
	All	3	4	All	3	4	All	3 or 4
Hematologic								
Leukopenia	86.0	29.7	2.9	55.4	5.0	0.4	< .001	< .001
Neutropenia	89.6	31.9	44.8	58.3	18.3	2.9	< .001	< .001
Anemia	82.4	14.3	2.5	86.7	15.5	3.6	.165	.680
Thrombocytopenia	63.1	7.2	2.2	87.4	19.4	13.3	< .001	< .001
Nonhematologic								
Febrile neutropenia	7.2	6.8	0.4	1.1	1.1	0	< .001	< .001
Nausea	49.1	2.2	0	62.4	1.8	0	.002	.475
Vomiting	23.7	1.1	0	34.1	1.8	0	.007	.837
Diarrhea	20.8	1.1	0	32.6	3.2	0	.002	.302
Neuropathy: sensory	81.0	2.9	0	15.8	0.4	0	< .001	.668
Arthralgia	67.4	2.5	0	7.9	0	0	< .001	.357
Alopecia	76.7			9.3			< .001	

NOTE. Differences between the two arms were evaluated by the χ^2 test.

QOL

At random assignment, 99.6% of patients (562 of 564) completed baseline questionnaires, with the questionnaire completion rates being 93.4% at 6 weeks and 90.1% at 9 weeks. Compliance rates were not significantly different between the treatment arms. QOL data were missing in 38 surveys due to death or severe impairment of the patient's general condition, which accounted for 2.3% of the total number of the surveys scheduled. There was no significant difference in the lung cancer subscale of FACT-L between the treatment arms (Fig 4). Scores on the neurotoxicity subscale of FACT/GOG-Ntx had decreased significantly in the carboplatin and paclitaxel arm after two cycles of chemotherapy (Fig 4); the adjusted mean scores at 6 and 9 weeks were 41.2 and 41.0 for the carboplatin and S-1 arm and 38.2 and 37.1 for the carboplatin and paclitaxel arm. The alopecia score was also significantly worse in the carboplatin and paclitaxel arm than in the carboplatin and S-1 arm ($P < .001$, analysis of variance), with the adjusted means at 6 and 9 weeks being 3.8 and 3.7 for carboplatin and S-1 and 1.7 and 1.9 for carboplatin and paclitaxel ($P < .001$ at both 6 and 9 weeks, Tukey-Kramer multiple-comparison test).

Poststudy Treatment

There were no major differences in poststudy treatment between the two arms. Overall, 69.4% of carboplatin and paclitaxel patients and 75.5% of carboplatin and S-1 patients received an additional line of therapy ($P = .103$, χ^2 test). Docetaxel was administered in 43.4% and 52.0% of patients and epidermal growth factor receptor tyrosine kinase inhibitors were administered in 24.0% and 27.2% of patients in the carboplatin and paclitaxel and carboplatin and S-1 arms, respectively.

DISCUSSION

Our phase III study is the first to evaluate the efficacy of an S-1-containing regimen in comparison with standard platinum-doublet chemotherapy for first-line treatment of patients with advanced NSCLC. The primary objective of the study—determination of the noninferiority of carboplatin and S-1 compared with carboplatin and paclitaxel in terms of OS—was met at the planned interim analysis.




Fig 4. Quality of life assessments with the (left) seven-item Functional Assessment of Cancer Therapy-Lung (FACT-L) and (right) 11-item FACT/Gynecology Oncology Group-Neurotoxicity (GOG-Ntx) scales. Data are least square means \pm 95% CI. Higher scores indicate better quality of life. P values shown were determined by analysis of variance, with P being less than .001 for comparison of FACT/GOG-Ntx scores between the two arms at both 6 and 9 weeks by the Tukey-Kramer multiple-comparison test.

Analysis of OS in the ITT and PP populations as well as in subgroups of the study subjects demonstrated the noninferiority of carboplatin and S-1. Although there was a significant difference in response rate favoring carboplatin and paclitaxel, disease control rate and PFS were similar for carboplatin and S-1 and carboplatin and paclitaxel. Given that subsequent therapies after discontinuation of the study treatment were well-balanced between the treatment groups, it is unlikely that poststudy therapy confounded survival results. Collectively, our secondary data indicate that the findings of the main analysis are robust. Although the protocol-specified noninferiority margin of 1.33 may be large, the survival curves themselves mostly coincided for the two treatment arms and median OS in the carboplatin and S-1 group was noteworthy at approximately 15 months.

The profile of adverse events associated with carboplatin and S-1 and carboplatin and paclitaxel was as expected, but there were marked differences in the incidence of some of these events. Carboplatin and paclitaxel treatment resulted in a typically high incidence of neutropenia of grade 3 or 4 (76.7%) as well as of febrile neutropenia (7.2%), compared with incidences of only 21.1% and 1.1%, respectively, for carboplatin and S-1. These rates of neutropenia associated with carboplatin and paclitaxel treatment are consistent with those observed in previous studies of Japanese patients.^{11,14} Carboplatin and S-1 treatment showed a significantly higher rate of thrombocytopenia, which was the most frequent reason for dose delays in the carboplatin and S-1 group. However, this condition was considered manageable because it was associated with bleeding of grade 3 in only one patient. With regard to nonhematologic toxicities, neuropathy, arthralgia, and alopecia were much less frequent in patients treated with carboplatin and S-1 than in those receiving carboplatin and paclitaxel. Consistent with these results, carboplatin and S-1 treatment showed a clinically relevant improvement in QOL as assessed by the FACT/GOG-Ntx scale and alopecia score. Despite these QOL benefits with carboplatin and S-1, however, there was no significant difference in FACT-L score between carboplatin and S-1 and carboplatin and paclitaxel, possibly because of other more toxic effects of carboplatin and S-1. The incidence of nausea, vomiting, and diarrhea of any grade was higher in patients assigned to the carboplatin and S-1 arm than in those assigned to carboplatin and paclitaxel, although grades 3 or 4 of these toxicities were uncommon (< 4%) in both groups. The relative dose intensity of S-1 was 94.3% in the carboplatin and S-1 arm (median of four cycles administered), and treatment was discontinued in only approximately 10% of patients in this arm because of adverse events. Overall, these data indicate that carboplatin and S-1 was well-tolerated, with continuation of treatment as specified in the protocol not being a problem. According to our previous phase I/II study of carboplatin and S-1,⁹ this study excluded elderly (≥ 75 years old) patients. Given its efficacy

and favorable toxicity profile, the combination of S-1 and carboplatin warrants further evaluation in elderly patients.

In conclusion, our present study demonstrates the noninferiority of carboplatin and S-1 relative to carboplatin and paclitaxel in terms of OS for patients with advanced NSCLC. Carboplatin and S-1 is therefore a valid therapeutic option for the first-line treatment of patients with advanced NSCLC.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: None **Consultant or Advisory Role:** Takayasu Kurata, Takeda Pharmaceutical (U) **Stock Ownership:** None **Honoraria:** Isamu Okamoto, Chugai Pharmaceutical, Eli Lilly; Miyako Satouchi, Chugai Pharmaceutical, AstraZeneca; Takayasu Kurata, AstraZeneca, Eli Lilly; Masahiro Fukuoka, AstraZeneca, Daiichi Sankyo, Boehringer Ingelheim, Chugai Pharmaceutical; Kazuhiko Nakagawa, Taiho Pharmaceutical, Bristol-Myers Squibb **Research Funding:** None **Expert Testimony:** None **Other Remuneration:** None

AUTHOR CONTRIBUTIONS

Conception and design: Isamu Okamoto, Satoshi Morita, Masahiko Ando, Koji Takeda, Takashi Seto, Nobuyuki Yamamoto, Hideo Saka, Tomonori Hirashima, Miyako Satouchi, Toshiyuki Sawa, Masahiro Fukuoka, Kazuhiko Nakagawa

Administrative support: Kenji Tamura, Takayasu Kurata, Masahiro Fukuoka, Kazuhiko Nakagawa

Provision of study materials or patients: Isamu Okamoto, Hiroshige Yoshioka, Koji Takeda, Takashi Seto, Nobuyuki Yamamoto, Hideo Saka, Kazuhiro Asami, Tomonori Hirashima, Shinzoh Kudoh, Miyako Satouchi, Norihiko Ikeda, Yasuo Iwamoto, Toshiyuki Sawa, Masaki Miyazaki, Kenji Tamura

Collection and assembly of data: Isamu Okamoto, Hiroshige Yoshioka, Satoshi Morita, Masahiko Ando, Koji Takeda, Takashi Seto, Nobuyuki Yamamoto, Hideo Saka, Kazuhiro Asami, Tomonori Hirashima, Miyako Satouchi, Norihiko Ikeda, Yasuo Iwamoto, Toshiyuki Sawa, Masaki Miyazaki, Kenji Tamura, Takayasu Kurata

Data analysis and interpretation: Isamu Okamoto, Hiroshige Yoshioka, Satoshi Morita, Masahiko Ando, Nobuyuki Yamamoto, Kenji Tamura, Kazuhiko Nakagawa

Manuscript writing: All authors

Final approval of manuscript: All authors

REFERENCES

- Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. *CA Cancer J Clin* 59:225-249, 2009
- Azzoli CG, Baker S Jr, Temin S, et al: American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. *J Clin Oncol* 27:6251-6266, 2009
- Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med* 355:2542-2550, 2006
- Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol* 26:3543-3551, 2008
- Reck M, von Pawel J, Zatloukal P, et al: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. *J Clin Oncol* 27:1227-1234, 2009
- Shirasaka T, Nakano K, Takechi T, et al: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydropyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. *Cancer Res* 56:2602-2606, 1996
- Okamoto I, Fukuoka M: S-1: A new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. *Clin Lung Cancer* 10:290-294, 2009
- Kawahara M, Furuse K, Segawa Y, et al: Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. *Br J Cancer* 85:939-943, 2001

9. Tamura K, Okamoto I, Ozaki T, et al: Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. *Eur J Cancer* 45:2132-2137, 2009

10. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 92:205-216, 2000

11. Ohe Y, Ohashi Y, Kubota K, et al: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-arm cooperative study in Japan. *Ann Oncol* 18:317-323, 2007

12. Cella DF, Bonomi AE, Lloyd SR, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. *Lung Cancer* 12:199-220, 1995

13. Cella D, Peterman A, Hudgens S, et al: Measuring the side effects of taxane therapy in oncology: The functional assessment of cancer therapy-taxane (FACT-taxane). *Cancer* 98:822-831, 2003

14. Kubota K, Kawahara M, Ogawara M, et al: Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: A randomised, open-label, phase III study. *Lancet Oncol* 9:1135-1142, 2008

Journal of Clinical Oncology: The Ideal Place to Publish Your Research

- **Impact Factor of 17.793:** *JCO*'s published articles were cited 104,253 times and accounted for fully 9.7% of all oncology journal citations in 2009.
- **Rapid Turnaround:** *JCO* averages just 9 weeks from final manuscript acceptance to online publication.
- **Maximum Exposure:** More than 25,000 of the world's leading oncology professionals receive *JCO* and more than 300,000 unique visitors per month visit jco.org.
- **No Exclusivity Clause:** Authors may reproduce or reuse their own material published in *JCO* for educational purposes at no charge.
- **Outstanding Reputation:** With an acceptance rate of less than 15%, *JCO* publishes only the highest quality manuscripts across all oncology disciplines.
- **International Coverage:** *JCO* is available globally in 28 countries and in 15 international editions.

To submit a manuscript, visit submit.jco.org.



American Society of Clinical Oncology